UKX

(2S)-2-(2-oxidanylidenepyrrolidin-1-yl)butanamide


Toggle HydrogenToggle Labels

Chemical Component Summary

Name(2S)-2-(2-oxidanylidenepyrrolidin-1-yl)butanamide
Synonymslevetiracetam
Identifiers(2~{S})-2-(2-oxidanylidenepyrrolidin-1-yl)butanamide
FormulaC8 H14 N2 O2
Molecular Weight170.209
TypeNON-POLYMER
Isomeric SMILESCC[C@@H](C(=O)N)N1CCCC1=O
InChIInChI=1S/C8H14N2O2/c1-2-6(8(9)12)10-5-3-4-7(10)11/h6H,2-5H2,1H3,(H2,9,12)/t6-/m0/s1
InChIKeyHPHUVLMMVZITSG-LURJTMIESA-N

Chemical Details

Formal Charge0
Atom Count26
Chiral Atom Count1
Bond Count26
Aromatic Bond Count0

Drug Info: DrugBank

DrugBank IDDB01202 
NameLevetiracetam
Groups approved
DescriptionLevetiracetam is a drug within the pyrrolidine class that is used to treat various types of seizures stemming from epileptic disorders. It was first approved for use in the United States in 1999 and is structurally and mechanistically unrelated to other anti-epileptic drugs (AEDs).[L8606,L8600,L8615] Levetiracetam possesses a wide therapeutic index[L8615,A185918] and little-to-no potential to produce, or be subject to, pharmacokinetic interactions[L8606,L8600,L8615] - these characteristics make it a desirable choice over other AEDs, a class of drugs notorious for having generally narrow therapeutic indexes and a propensity for involvement in drug interactions.[A185927]
Synonyms
  • Levetiracetamum
  • Levetiracetam
  • Levetiracetame
Brand Names
  • Levetiracetam Actavis
  • Levetiracetam 750 mg
  • Levetiracetam Actavis Group
  • Roweepra XR
  • Sandoz Levetiracetam
IndicationLevetiracetam is indicated as an adjunctive therapy in the treatment of partial onset seizures in epileptic patients who are one month of age and older. Additionally, it is indicated as an adjunct in the treatment of myoclonic seizures in patients with juvenile myoclonic epilepsy who are 12 years of age and older, and in primary generalized tonic-clonic seizures in patients with idiopathic generalized epilepsy who are 6 years of age and older.[L8606] Levetiracetam is also available as an orally dissolvable tablet that is indicated as an adjunct in the treatment of partial onset seizures in patients with epilepsy who are 4 years of age and older and weigh more than 20kg.[L8609]
Categories
  • Acetamides
  • Amides
  • Anticonvulsants
  • Central Nervous System Agents
  • Central Nervous System Depressants
ATC-CodeN03AX14
CAS number102767-28-2

Drug Targets

NameTarget SequencePharmacological ActionActions
Voltage-dependent N-type calcium channel subunit alpha-1BMVRFGDELGGRYGGPGGGERARGGGAGGAGGPGPGGLQPGQRVLYKQSIA...unknowninhibitor
Synaptic vesicle glycoprotein 2AMEEGFRDRAAFIRGAKDIAKEVKKHAAKKVVKGLDRVQDEYSRRSYSRFE...unknownagonist
P-glycoprotein 1MDLEGDRNGGAKKKNFFKLNNKSEKDKKEKKPTVSVFSMFRYSNWLDKLY...unknownsubstrate
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
Pharos CHEMBL1286
PubChem 5284583
ChEMBL CHEMBL1286
ChEBI CHEBI:6437